EU Science Hub

Science updates

Nanoconjugate of gold nanoparticle with single-chain anti-TIM-3 antibody used for the detection of malignant leukeamia cells.
©EU,2018
Jul 31 2018

JRC scientists, in close collaboration with several European research organisations, have developed highly specific gold nanoparticles targeting malignant blood cancer cells. Such targeted nanocarriers enable the delivery of otherwise toxic drugs into the leukaemia cells and they can also serve a better diagnosis and treatment of leukemia.

Raman confocal microscope at the JRC Nanobiotechnology Laboratory
©EU, 2018
Jul 25 2018

JRC scientists contributed to a study paving the way to an easy production of biohybrid photonic nanostructures by simply feeding diatoms microalgae with tailored photoactive molecules.

Biotechnological processes harnessing living organisms' metabolism are low‐cost routes to nanostructured materials for applications in photonics, electronics, and nanomedicine. Some living organisms have optimised their ability to generate photoactive components – essential for their survival – with macro- to nanoscale structures.

Gold nanoparticles
©Kateryna_Kon, stock.adobe.com
Jul 17 2018

JRC scientists have developed methods for the in-depth characterization of multi-functionalized gold nanoparticles. This will support the development of advanced nanomaterials for health applications.

Multi-functionalized nanoparticles are of great interest for diagnostic and therapeutic applications. However, at the moment the characterization of complex, multifunctional nanoparticles is still challenging and this hampers the development of these advanced materials for health applications.

Need for harmonization in regulatory testing of nanomedicines
©wladimir1804 stock.adobe.com
Jul 10 2018

JRC scientists, in close collaboration with Norwegian SINTEF Institute for Materials and Chemistry, have conducted a survey among regulatory scientists of nine international competent authorities with the aim to obtain a general overview on the current status and regulatory needs of nanomedicines.

AUC sample, JRC Nanobiotechnology Laboratory
©EU, 2018
Jun 15 2018

JRC scientists contributed to an intra-laboratory study comparing the outcome of analytical results using ultracentrifugation for the identification of nanomaterials. This is important for the registration or authorisation process related to the nanoparticle content of various chemicals, cosmetic or food products.

Judging whether a material is a nanomaterial for regulatory purposes in Europe is based on measuring the relative number of particles above and below a 100 nm threshold.

Need for suitable methods assessing the quality and safety of nanomedicines
©Kateryna Kon - adobe.stock.com
Jun 05 2018

JRC scientists – in close collaboration with researchers from the French CEA and Irish Trinity College – have demonstrated some shortcomings of currently used test methods when applied to the characterisation and safety assessments of medical-nanoparticles. There is a need to further assess the suitability of existing standardised methods used for safety and quality evaluations, especially for the next generation of nanomedicines.

Polystyrene nanoparticles of 100 nm in diameter acquired by scanning electron microscopy
©EU, 2018
Jun 04 2018

Reliable and reproducible characterisation of nanomaterials has become a key challenge to understanding nanomaterial biocompatibility, risk assessment and possible toxicity mechanisms. JRC scientists contributed to the assessment of the reproducibility of two popular nanoparticle characterisation techniques, dynamic light scattering and differential centrifugal sedimentation.

NANoREG Toolbox
©Sergey Ilin - stock.adobe.com
Mar 16 2018

JRC scientists have developed the first comprehensive inventory of publicly available tools that are ready to be used for nanomaterial safety assessment. 

Nanomaterial characterisation in the JRC Nanobiotechnology Laboratory
©@EU 2018
Feb 12 2018

Experts from several German and French organisations - including scientists from EFSA and the JRC - reviewed the current application of classical and new nanomaterials in the context of regulatory requirements and standardisation for chemicals, food and consumer products. They concluded that nanomaterial characterisation is still challenging and the major bottleneck of risk assessment and regulation.

'Bridging communities in the field of nanomedicine', JRC, Ispra, 27th-28th September 2017
©EU, 2017
Dec 11 2017

The JRC organised a dedicated workshop to bridge scientific communities involved in progressing the regulatory science of nanomedicines. There was a general agreement by the participants that existing standards and guidance documents might not be always sufficient for the regulation of nanomedicines due to their particularities.

Pages

JRC wide hidden block